ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0433

Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey

Lukas Joos1, Solange Gonzalez Chiappe1, Thomas Neumann1 and Alfred Mahr2, 1Kantonsspital St.Gallen, St.Gallen, Switzerland, 2Kantonsspital St. Gallen, St.Gallen, Switzerland

Meeting: ACR Convergence 2021

Keywords: ANCA associated vasculitis, cyclophosphamide, Mesna

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Saturday, November 6, 2021

Title: Vasculitis – ANCA-Associated Poster (0414–0436)

Session Type: Poster Session A

Session Time: 8:30AM-10:30AM

Background/Purpose: Co-prescribing mesna with CYC for AAV aims to prevent the potential urotoxic effects of CYC. We investigated current clinical practice related to prescribing mesna prophylaxis or not for CYC-treated patients with AAV.

Methods: We searched MEDLINE for publications with the MeSH term “ANCA-associated vasculitis” over a 10-year period. Email addresses of authors were extracted from the online information. These authors were invited by email to participate in an online SurveyMonkey® survey asking about the characteristics of the respondent, their experience with AAV, and their practice in using CYC to treat AAV and in using mesna in CYC-treated patients with AAV and the underlying rationale. We compared 15 response variables to identify factors associated with the use of mesna. Response variables with multiple categories were first analyzed across all categories; if the omnibus test result was significant, additional analyses were used to identify the categories, which were the sources of group separation. Statistical analyses involved Pearson’s chi-square test or Fisher’s exact test. For multiple-response variables, the Rao-Scott correction was applied.

Results: The 139 participants were from 34 countries and were essentially MDs (98%) who mainly worked in rheumatology (50%), nephrology (25%) or internal medicine/immunology (18%). Mesna was given with CYC systematically, never, or on a case-by-case basis by 68%, 19% and 13% of respondents, respectively. As compared with systematic mesna-prescribers, never/occasional mesna-prescribers reported a longer time since receiving their degree (≥ 15 years: 80% vs 50%, P< 0.001), were more frequently based in England/United States (than in France/Germany/Italy) (78% vs 21%, P< 0.001), had longer involvement in care of patients with AAV (≥15 years: 62% vs 37%, P=0.006), had less practice in using intermittent pulse therapy as the exclusive/predominant CYC administration scheme (62% vs 89%, P< 0.001), and, as a rationale underpinning their mesna practice, had less adherence to local operational procedures (47% vs 73%, P=0.002) or (inter)national management guidelines for AAV (16% vs 49%, P< 0.001).

Conclusion: Practice with regard to prescribing mesna in conjunction with CYC to treat AAV is heterogeneous. Systematic mesna use prevailed over never or occasional use. The decision to prescribe mesna may be based more on circumstantial than structural reasons.


Disclosures: L. Joos, None; S. Gonzalez Chiappe, None; T. Neumann, None; A. Mahr, Celgene, 2, Chugai, 2, 6, Roche, 6, Amgen, 1, 6.

To cite this abstract in AMA style:

Joos L, Gonzalez Chiappe S, Neumann T, Mahr A. Use of 2-Mercaptoethane Sodium Sulfonate Prophylaxis in Cyclophosphamide-Treated Patients with ANCA-Associated Vasculitis: Results of an Electronic Survey [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/use-of-2-mercaptoethane-sodium-sulfonate-prophylaxis-in-cyclophosphamide-treated-patients-with-anca-associated-vasculitis-results-of-an-electronic-survey/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/use-of-2-mercaptoethane-sodium-sulfonate-prophylaxis-in-cyclophosphamide-treated-patients-with-anca-associated-vasculitis-results-of-an-electronic-survey/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology